TITLE

Genetic Roadmap Links Drugs and Disease

PUB. DATE
December 2006
SOURCE
Science Teacher;Dec2006, Vol. 73 Issue 9, p15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on a program to explain how certain drugs treat diseases. The Connectivity Map, created by scientists from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute, and the Howard Hughes Medical Institute, is a database designed to help doctors and scientists understand the interactions between certain drugs and diseases.
ACCESSION #
23327179

 

Related Articles

  • ImClone/BMS/Merck KGaA: Erbitux approval in lung cancer now likely.  // PharmaWatch: Cancer;Jul2008, Vol. 7 Issue 7, p12 

    The article reports on the efficacy of Erbitux to increase survival in advanced non-small lung cancer (NSCLC). Based on the First-Line Treatment for Patients with epidermal growth factor receptor (EGFR)-Expressing Advanced NSCLC (FLEX) trial versus chemotherapy, overall survival was 11.3 months...

  • Chimiothérapie des CAPI: quelles leçons peut-on en tirer en 2008? Massard, C.; Fizazi, K. // Oncologie;Dec2008, Vol. 10 Issue 12, p728 

    Chemotherapy is the backbone of treatment for patients with CUP. Most patients with unknown primary adenocarcinoma or poorly differentiated carcinoma do not conform to any previously defined “treatable” or favourable subset. To our knowledge, no randomized trial comparing...

  • The Increasing Complexity of Mercaptopurine Pharmacogenomics. Marsh, S.; Van Booven, D. J. // Clinical Pharmacology & Therapeutics;Feb2009, Vol. 85 Issue 2, p139 

    Thiopurine methyltransferase (TPMT) activity shows significant interindividual variation, with approximately 90% of individuals having high (wild-type) activity, 10% with intermediate activity, and 0.3% with low activity. Low and intermediate TPMT activity leads to toxicity from mercaptopurine...

  • Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity. Fuso Nerini, I; Morosi, L; Zucchetti, M; Ballerini, A; Giavazzi, R; D'Incalci, M // Clinical Pharmacology & Therapeutics;Aug2014, Vol. 96 Issue 2, p224 

    We provide an overview of the available information on the distribution of chemotherapeutics in human tumors, highlighting the progress made to assess the heterogeneity of drug concentrations in relation to the complex neoplastic tissue using novel analytical methods, e.g., mass spectrometry...

  • Highlights.  // Clinical Pharmacology & Therapeutics;Aug2014, Vol. 96 Issue 2, p128 

    The article discusses several studies about clinical pharmacology and therapeutics. Topics discussed include comparison between clinically-guided and genotype-guided dosing of warfarin, the use of copper-chelating drugs for treating cancers positive for BRAF mutation, and the modulation of the...

  • stronger bones on the cards. Duncan, Debbie // Good Medicine (Australian Consolidated Press);Apr2005, p11 

    Provides an overview of a research being done at the University of Texas Southwestern Medical Center which examines the effectiveness of an injectable drug in reducing bone loss and strengthening the bones.

  • Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Erdlenbruch, Bernhard; Nier, Marit; Kern, Wolfgang; Hiddemann, Wolfgang; Pekrun, Arnulf; Lakomek, Max // European Journal of Clinical Pharmacology;Aug2001, Vol. 57 Issue 5, p393 

    Background: Cisplatin is a highly effective and frequently used drug in the chemotherapy of solid tumours in children, but only limited data are available on the pharmacokinetics of cisplatin and its associated nephrotoxicity in paediatric patients. Methods: We investigated the pharmacokinetics...

  • Benefit-Risk Analysis: A Brief Review and Proposed Quantitative Approaches. Holden, William L. // Drug Safety;Sep2003, Vol. 26 Issue 12, p853 

    Given the current status of benefit-risk analysis as a largely qualitative method, two techniques for a quantitative synthesis of a drug?s benefit and risk are proposed to allow a more objective approach. The recommended methods, relative-value adjusted number-needed-to-treat (RV-NNT) and its...

  • Molecular Medicine Hones Therapeutic Arts to Science. Waldman, S. A.; Terzic, M. R.; Terzic, A. // Clinical Pharmacology & Therapeutics;Oct2007, Vol. 82 Issue 4, p343 

    The article presents information on the advances made in the drug discovery development regulation utilization (DDRU). It alludes the contribution of molecular medicine in revolutionizing the nodes along DDRU. It states that though significant achievements have been accomplished in the science...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics